India, March 6 -- Shares of Plus Therapeutics, Inc. (PSTV) were surging around 80 percent in the pre-market activity on the Nasdaq after the company announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation or ODD to Rhenium (186Re) Obisbemeda for the treatment of leptomeningeal metastases (LM) in patients with lung cancer.
LM is a rare complication of cancer in which the primary cancer spreads to the cerebrospinal fluid (CSF) and leptomeninges surrounding the brain and spinal cord.
Rhenium (186Re) obisbemeda is a novel injectable radiotherapy specifically formulated to deliver highly targeted high dose radiation in central nervous system or CNS tumors in a safe, effective and convenient manner. It has the p...